Neurotech International Ltd. (AU:NTI) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurotech International Ltd, a clinical-stage biopharmaceutical company specializing in pediatric neurological disorders, successfully held its Annual General Meeting, with all resolutions carried. The company, known for its NTI164 cannabinoid drug therapy, has shown significant promise in trials for Autism Spectrum Disorder and other neurological conditions. Investors might find potential growth opportunities as Neurotech advances its clinical trials in spastic cerebral palsy.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.